Home
Portfolio
News
Contact
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
CG Oncology
related
news
ADARx Pharmaceuticals raises 4.463 million in upsized US IPO
Reuters
September 25 2026
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NASDAQ
July 14 2026
Get In Touch
Contact Us